Company / SG&A Expense
OMEROS CORP SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$49.7M
FY2024
5-year range
$49.3M / $54.8M
FY2020-FY2024
Trend
+0.2%
vs FY2023
Sector context
#160 of 213
Health Care
What the data says
OMEROS CORP's sg&a expense of $50M is lower than 75% of companies in the Health Care sector (FY2024). SG&A Expense returned to growth in FY2024 after 2 years of decline, reaching $50M.
Based on SEC 10-K filings.
$50M in FY2024 with a 5-year CAGR of +4.6%.
Remained stable around $50M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -3.2%
- 5-Year CAGR
- +4.6%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 213This company $49.7M Sector average $722.3M
▼
-93.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.6%, indicating consistent growth.
- In FY2024, sg&a expense increased 0.2% year-over-year.
- Ranks #160 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $49.7M | +0.2% |
| FY2023 | $49.7M | -2.0% |
| FY2022 | $50.7M | -7.6% |
| FY2021 | $54.8M | +11.2% |
| FY2020 | $49.3M | +24.2% |
| FY2019 | $39.7M | -23.2% |
| FY2018 | $51.7M | -0.6% |
| FY2017 | $52.0M | +18.9% |
| FY2016 | $43.8M | +176.8% |
| FY2015 | $15.8M | -30.0% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026